Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Basilea Pharmaceutica's Enterprise Value for the quarter that ended in Dec. 2025 was CHF601.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF49.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's EV-to-EBIT falls into.
Basilea Pharmaceutica's current Enterprise Value is CHF571.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF49.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a EV-to-EBIT of 11.61 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Basilea Pharmaceutica and its competitors. According to the industry distribution chart, Basilea Pharmaceutica ranks #188 out of 387 companies in the Biotechnology industry, placing it in the top 48.6%.
Is Basilea Pharmaceutica's EV-to-EBIT too high?
Basilea Pharmaceutica's current EV-to-EBIT is 11.61. The Biotechnology industry median EV-to-EBIT is 12.63. Basilea Pharmaceutica's value of 11.61 is 8.1% below this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #188 out of 387 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #188 out of 387 companies for EV-to-EBIT. This puts Basilea Pharmaceutica in the upper half of its industry. The industry median EV-to-EBIT is 12.63. Basilea Pharmaceutica's value of 11.61 is 8.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current EV-to-EBIT of 11.61 is 8.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current EV-to-EBIT is 11.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF58.01, compared to a current price of CHF51.90 — trading 10.5% below its estimated fair value. The current EV-to-EBIT is 11.61 and 8.1% below the Biotechnology industry median of 12.63. Basilea Pharmaceutica's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current EV-to-EBIT is 11.61 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF51.90 is trading 10.5% below its estimated GF Value™ of CHF58.01.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
EV-to-EBIT: 11.61
GF Value™: CHF58.01 vs. price of CHF51.90 (10.5% below fair value)
Industry Position: 8.1% below the Biotechnology median (#188 of 387)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
60GF Score
Get the complete analysis for XSWX:BSLN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
